Skip to main content
News Icon

New Speaker and Executive Board Member

Prof. Joachim L. Schultze from the LIMES Institute Bonn resigned in his position as speaker and member of the executive board of the Cluster of Excellence.

We wish him all the best for his future tasks in the field of immunology and we are more then happy that he supports the Cluster of Excellence ImmunoSensation as a member of the steering committe and valuable group leader.

As a succesor for the speaker position Prof. Waldemar Kolanus and as succesor for the executive board member position Prof. Elvira Mass, both from the LIMES Institute in Bonn, will replace Prof. Joachim L. Schultze.

Welcome Prof. Kolanus and Prof. Mass in your new roles in the Cluster of Excellence ImmunoSensation2.

Related news

Student Course

Outreach

We're Becoming Researchers – Children's Science Workshop in Bonn-Oberkassel

—How do you actually plan an experiment, and what do scientists do all day? These questions and many more were explored firsthand during a two-day children’s science workshop on April 20 and 27, 2026, in Bonn-Oberkassel. In total, 15 children aged 7 to 12 took part.
View entry
MS Wissenschaft Wachten Vonderheidt

Event Outreach

University of Bonn Exhibit at MS Wissenschaft Parliamentary Reception

—MS Wissenschaft is back on tour through Germany, Austria, and Poland. At the parliamentary reception aboard MS Wissenschaft on May 7 in Berlin, the University of Bonn, a University of Excellence, presented its exhibit to leading representatives from politics, science, and society. The Federal Ministry for Research, Transfer and Space (BMFTR) and the organizer, Science in Dialogue, selected Bonn’s exhibit as one of only three out of the roughly 30 exhibits aboard the exhibition ship for the evening event.
View entry
News Icon

Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

—A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry

Back to the news overview